BioAge Labs, Inc. BIOA

BIOA Company Overview

BioAge Labs, Inc. (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases by targeting the biological mechanisms of aging. The company operates within the biotechnology and pharmaceutical industries, with a primary emphasis on obesity, cardiometabolic disease, and related chronic conditions. BioAge’s strategy combines human longevity datasets, biomarker discovery, and drug development to identify molecular pathways associated with aging that may influence metabolic health and disease progression.

The company’s primary revenue and value drivers are tied to the advancement of its therapeutic pipeline, research collaborations, and intellectual property portfolio rather than commercial product sales, as BioAge remains in the clinical development stage. BioAge was founded in 2015 and evolved from research leveraging longitudinal human aging datasets designed to identify biological pathways associated with healthy aging and disease risk. Its positioning is differentiated by its integration of computational biology, human cohort data, and drug development capabilities aimed at translating aging science into therapeutics for obesity and metabolic disorders.